If you are here about treatment, start here.
In brief
- Universities, hospitals, nonprofits and government bodies sponsor 233 of the 328 psilocybin trials on the register at 5 September 2026. The sponsor is not always the organization that supplies the drug: Filament Health Corp. supplies it in 16 trials and sponsors one.
What cannabis did last time
Four cannabis-related medicines completed the FDA route, Marinol and Cesamet in 1985, Syndros in 2016 and Epidiolex in 2018, and none of them is the plant. The plant is still in Schedule I, and its rescheduling docket reached notice of hearing on 28 April 2026, which is a stage and not an outcome.
Cannabis had a retail channel from its first day, where every psilocybin route on this map is clinical or supervised, so the mechanism that moved the cannabis number does not exist here. The unlicensed leg of the series below is also a modelled national-accounts estimate, which makes every share on it partly a model.
With both of those attached, the licensed route in Canada took 12.8 percent of household spending on non-medical cannabis in the quarter legal sales began, 24.3 percent across 2019 and 70.8 percent across 2025, on Statistics Canada figures read on 7 September 2026. Nothing on the psilocybin map has a decade of data.
Who pays for the trials
A trial’s sponsor is whoever takes legal responsibility for running it, which is not necessarily whoever paid for it. On that reading, the 328 trials on the register at 5 September 2026 split into 233 public or academic sponsors, 38 companies, 43 unclassified and 14 filed by a named individual. The company figure is a floor, because an unclassified row may well be a company nobody has typed yet.
Some organizations appear in more trials as the supplier of the study drug than as the sponsor. On that same read, Filament Health Corp. supplies the drug in 16 trials and sponsors one, and Usona Institute supplies 11 and sponsors four. A sponsor index cannot see either of them, which is most of why nobody can tell you who supplies this field.
Company-typed starts move, and the most recent of the series’ eight buckets is an incomplete year. With that in front, they peaked at 11 in 2022 and were 6 in 2025, while total starts went from 30 to 58 between those two years.
On that same 5 September 2026 read, 175 of the 328 name nothing that points at a funder, 12 join a grant record by grant number and 301 name no grant identifier. The grant field is registry housekeeping that sponsors fill in at their discretion, and no registry behind this corpus published an amount for any trial in it.
Where the listed companies sit
Eli Lilly agreed to buy AtaiBeckley on 15 July 2026, as AtaiBeckley’s own quarterly filing (opens in new tab) states. Seven listed companies had a psilocybin business when this register was last read on 7 September 2026, and every one of them is a parent company.
In their own filings, four state a psilocybin molecule of their own, one is a licensed producer in the words of its Form F-1/A of 13 March 2026, one reaches psilocybin only through a wholly owned subsidiary, and one carries a programme that is not psilocybin at all.
| Listed parent | Trials in its own name | Chain, quoted from its own annual document | Symbol and exchange |
|---|---|---|---|
| AtaiBeckley Inc. | None | Not stated in the annual documents read for this piece | ATAI · Nasdaq Stock Market LLC |
| COMPASS Pathways plc | None | COMPASS Pathways plc to Compass Pathfinder Holdings to Compass Pathfinder (10-K, 24 Mar 2026) | CMPS · Nasdaq Global Select Market |
| Cybin Inc. | None | Cybin Inc. to Helus Pharma Corp. to Cybin IRL (Annual Information Form) | HELP · Nasdaq Stock Market LLC |
| Incannex Healthcare Inc. | None | Incannex Healthcare Inc. to Incannex Healthcare Pty Ltd (10-K) | IXHL · Nasdaq Capital Market |
| Jaguar Health, Inc. | None | Not stated in the annual documents read for this piece | JAGX · Nasdaq Capital Market |
| Psyence Biomedical Ltd. | None | Not stated in the annual documents read for this piece | PBM · Nasdaq Stock Market LLC |
| Optimi Health Corp. | One, withdrawn with no participants enrolled | Not stated in the annual documents read for this piece | OPTH · Nasdaq |
AtaiBeckley Inc.
- Trials in its own name:
- None
- Chain, quoted from its own annual document:
- Not stated in the annual documents read for this piece
- Symbol and exchange:
- ATAI · Nasdaq Stock Market LLC
COMPASS Pathways plc
- Trials in its own name:
- None
- Chain, quoted from its own annual document:
- COMPASS Pathways plc to Compass Pathfinder Holdings to Compass Pathfinder (10-K, 24 Mar 2026)
- Symbol and exchange:
- CMPS · Nasdaq Global Select Market
Cybin Inc.
- Trials in its own name:
- None
- Chain, quoted from its own annual document:
- Cybin Inc. to Helus Pharma Corp. to Cybin IRL (Annual Information Form)
- Symbol and exchange:
- HELP · Nasdaq Stock Market LLC
Incannex Healthcare Inc.
- Trials in its own name:
- None
- Chain, quoted from its own annual document:
- Incannex Healthcare Inc. to Incannex Healthcare Pty Ltd (10-K)
- Symbol and exchange:
- IXHL · Nasdaq Capital Market
Jaguar Health, Inc.
- Trials in its own name:
- None
- Chain, quoted from its own annual document:
- Not stated in the annual documents read for this piece
- Symbol and exchange:
- JAGX · Nasdaq Capital Market
Psyence Biomedical Ltd.
- Trials in its own name:
- None
- Chain, quoted from its own annual document:
- Not stated in the annual documents read for this piece
- Symbol and exchange:
- PBM · Nasdaq Stock Market LLC
Optimi Health Corp.
- Trials in its own name:
- One, withdrawn with no participants enrolled
- Chain, quoted from its own annual document:
- Not stated in the annual documents read for this piece
- Symbol and exchange:
- OPTH · Nasdaq
The second column counts trials this register joins to the company itself; nine trials filed under “COMPASS Pathways” are joined to no company.
About this table
Eleven trials on this register reach one of the seven. Ten reach it through a subsidiary, which is the sponsor of record on the trial; the eleventh is the one counted in this column, and it was withdrawn with no participants enrolled. This column is counted off the axis's own edges rather than asserted, after an earlier version printed None seven times on the strength of a summary row and one of the seven cells was false.
Optimi Health states three symbols in one sentence of its own prospectus: OPTH on Nasdaq, OPTI on the Canadian Securities Exchange and 8BN on the Frankfurt Stock Exchange. The Nasdaq symbol is printed here and the other two are named in this note rather than chosen silently.
COMPASS Pathways registers American Depositary Shares, each representing one ordinary share, and not the ordinary shares themselves. Psyence Biomedical registers a second class, a warrant, which is not printed here.
A chain appears only where an issuer's own annual document states it. Four of the seven are blank because nothing read for this piece states theirs, which is a fact about what was read.
Nine psilocybin trials on ClinicalTrials.gov name “COMPASS Pathways” as lead sponsor. That name has been carried by both COMPASS Pathways plc and its subsidiary, so the register joins these trials to neither company and they are counted in no cell here.
The molecule test undercounts the capital in the room. An issuer that is not among the seven names psilocybin twice in its own annual report, both times about somebody else’s candidate.
AtaiBeckley completed its acquisition of Beckley Psytech Limited on 5 November 2025, stated in its own annual report (opens in new tab). Magdalena Biosciences, a joint venture formed by Jaguar Health and Filament Health Corp., is stated in an 8-K exhibit of 21 April 2026 (opens in new tab).
The register joins eleven trials to one of the seven through a filing that states the relationship, and ten of them run through a subsidiary, which is the sponsor of record. The eleventh is sponsored in Optimi Health Corp.’s own name, and that trial (opens in new tab) was withdrawn with no participants enrolled.
Nine more psilocybin trials on ClinicalTrials.gov (opens in new tab)name “COMPASS Pathways” as lead sponsor, a name that COMPASS Pathways plc and its subsidiary have both carried, so the register joins them to neither company and they sit outside the eleven.
What no regulator has approved
No regulator has approved a psilocybin medicine, in anything read for this work.
The standing costs of being a lawful supplier are documented in this register almost entirely in United States law: how the tax code treats the business, whether a bank will hold the account, what a licence costs a year. This piece does not follow them, and a reader should not take their absence here for their absence anywhere.
The rest of the money map
A lawful supplier needs more than one permission, in the words of one producer’s Form F-1/A of 13 March 2026, and no single register lists who holds them: who is allowed to make psilocybin.
Eighteen market-research firms sell a figure for this field, and what they show of it on the pages anyone can read is its own piece: how big is the psychedelic drugs market.
Two American states have put psilocybin to a statewide vote, and both campaigns filed with a public campaign-finance register: who paid to change the law.
Where treatment is lawful
A patient can be treated lawfully in at least five countries, and none of the five routes is an approved medicine. The instruments are Australia’s authorised prescriber pathway; Switzerland’s exemption under BetmG Art. 8 Abs. 5, issued to a physician; Canada’s class exemption under section 56 of the CDSA, alongside its Special Access Program; Germany’s Härtefallprogramm under § 21 Abs. 2 Nr. 3 AMG and the AMHV; and New Zealand’s approval under regulation 22 of the Misuse of Drugs Regulations 1977.
BfArM’s register of confirmed hardship programmes (opens in new tab) carried 29 programmes on the 8 September 2026 read, and one psilocybin row: the Zentralinstitut für Seelische Gesundheit in Mannheim, for treatment-resistant depression. The register records the confirmed notification as received on 18 June 2026 and gives the programme an end date of 17 June 2027. What that register names is the institution responsible for the programme, which is not the room where any patient is treated, and one institution on one register is close to no data at all.
These routes run on clocks the criminal statutes do not have. Canada’s class exemption states on its own page (opens in new tab)that it will be revoked when new regulations take effect on 1 October 2026, and what replaces it after that date is not stated by anything read for this work. Switzerland’s own published page requires renewal at least two weeks before an exemption lapses, and states no period.
The reader’s edition
The reader’s edition of this work, with every figure and the full source trace, goes to people on our alerts list.
Corrections. Route pending, gated with publication.
Corrected 21 September 2026. An earlier version said none of the seven listed companies sponsors a trial in its own name, and its table showed none for Optimi Health Corp. ClinicalTrials.gov names Optimi Health Corporation as lead sponsor of NCT05252598, which was withdrawn with no participants enrolled. The headline, the summary and the table were revised with this correction.
Corrected 22 September 2026. The table now says that its second column counts only the trials this register joins to a company in its own name. Nine trials on ClinicalTrials.gov name COMPASS Pathways as lead sponsor, a name that COMPASS Pathways plc and its subsidiary have both carried, so the register joins them to neither company, and the page now says so beside the count.